Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
‘Don’t Buy the Dip,’ Says Morgan Stanley About Hims & Hers Stock
Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Hims & Hers bought a skincare startup for $190 million 4 years ago. Today it shut it down.
Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...
Why Hims & Hers Stock Just Collapsed
Hims & Hers Health ( HIMS -12.56%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...
Hims & Hers (HIMS) Investors Pulling Their Hair Out Over Pills Side-Effects
Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
Why Hims & Hers Health Stock Just Popped
Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...
This Could Be a Huge Blow to Hims & Hers Health Stock
Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...
Hims & Hers to shut down dermatology business Apostrophe
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth provider's lofty sales forecast on Tuesday amid looming restrictions on ...